We are live on ! Find out more
LSB

LakeShore Biopharma
LSB

Delisted

LSB was delisted on the 19th of September, 2025.

Back to rankings

7 hedge funds and large institutions have $330K invested in LakeShore Biopharma in 2025 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

5.89% less ownership

Funds ownership: 7.59% → 1.7% (-5.9%)

22% less funds holding

Funds holding: 9 → 7 (-2)

67% less capital invested

Capital invested by funds: $1.01M → $330K (-$685K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
7
Holders Change
-2
Holders Change %
-22.22%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
2
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$6.87K
2
Citadel Advisors
Citadel Advisors
Florida
+$5.5K

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$108K
2
Toronto Dominion Bank
Toronto Dominion Bank
Ontario, Canada
-$43K
3
TRCT
Tower Research Capital (TRC)
New York
-$686

LSB Hedge Fund Activity: Q2 2025 in Review

7 of the 7,614 institutional investors tracked by Wall St. Rank reported a position in LakeShore Biopharma (LSB) for Q2 2025, worth a combined $330K — down 67% from $1.01M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of LSB and 0 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 2 added.

The largest buyer was UBS Group, adding an estimated $6.87K. The largest seller was OrbiMed, cutting an estimated $108K.

  • 7 institutional investors held LakeShore Biopharma (LSB) as of Q2 2025, down from 9 in Q1 2025.
  • Funds reported $330K of LakeShore Biopharma stock for Q2 2025, down 67% quarter-over-quarter.
  • 0 funds opened new LakeShore Biopharma positions in Q2 2025 and 2 closed out, a net change of -2 holders.
  • The largest LakeShore Biopharma buyer in Q2 2025 was UBS Group, an estimated $6.87K added.
  • The largest LakeShore Biopharma seller in Q2 2025 was OrbiMed, an estimated $108K sold.

Based on aggregated 13F filings for Q2 2025.